| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Entheon Biomedical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.12 |
| 52 Week High | CA$0.29 |
| 52 Week Low | CA$0.043 |
| Beta | 1.55 |
| 1 Month Change | 7.38% |
| 3 Month Change | 69.72% |
| 1 Year Change | -28.54% |
| 3 Year Change | -95.85% |
| 5 Year Change | n/a |
| Change since IPO | -96.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENTB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.6% | 0.7% | 1.2% |
| 1Y | -28.5% | 5.0% | 27.7% |
Return vs Industry: ENTB.F underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: ENTB.F underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ENTB.F volatility | |
|---|---|
| ENTB.F Average Weekly Movement | 92.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ENTB.F's share price has been volatile over the past 3 months.
Volatility Over Time: ENTB.F's weekly volatility has increased from 50% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Timothy Ko | www.entheonbiomedical.com |
Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. The company is headquartered in Vancouver, Canada.
Entheon Biomedical Corp. Fundamentals Summary
| ENTB.F fundamental statistics | |
|---|---|
| Market cap | US$1.10m |
| Earnings (TTM) | -US$203.99k |
| Revenue (TTM) | US$95.20k |
11.6x
P/S Ratio-5.4x
P/E RatioIs ENTB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTB.F income statement (TTM) | |
|---|---|
| Revenue | CA$130.32k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$130.32k |
| Other Expenses | CA$409.59k |
| Earnings | -CA$279.27k |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 100.00% |
| Net Profit Margin | -214.29% |
| Debt/Equity Ratio | 0% |
How did ENTB.F perform over the long term?
See historical performance and comparison